Can Annexon Turn a Clinical-Stage Pipeline Into Evidence That Vision Preservation Matters More Than Lesion Growth?

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Annexon has not disclosed the specific timing of its Q3 2026 earnings release, but based on the scheduled date of November 9, 2026, the report is expected before market open, meaning Day 0 reflects the first full trading session where the market reacts to results, and Day +1 captures follow-through momentum.

Annexon's post-earnings price behavior has been moderately volatile, with an average absolute Day 0 move of 4.94% and an average Day +1 move of 3.34%. The Day 0 range averages 8.00%, indicating significant intraday swings, while the Day +1 range of 8.98% suggests continued volatility into the following session.

The direction of moves has been mixed, with no clear pattern. The most dramatic reaction came in March 2026, when the stock declined 0.80% on Day 0 but then surged 11.69% on Day +1, with a Day +1 range of 17.44%—the largest follow-through move in the dataset. This suggests that initial market reactions can be muted, with more significant repricing occurring as investors digest the details.

Recent earnings have shown more subdued reactions: the August 2026 report (Q2 2026) saw a negligible Day 0 move of -0.19% and a modest Day +1 move of -1.31%, despite the company missing estimates by 21.7%. This relatively calm response may reflect that the miss was already anticipated or that investors are focused on upcoming clinical catalysts rather than quarterly financials. However, the historical data shows that Annexon is capable of double-digit moves, particularly when earnings coincide with clinical or regulatory updates.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 18.62% (or $0.78) for the November 20, 2026 expiration, which is significantly higher than the stock's historical average post-earnings moves of 4.94% on Day 0 and 3.34% on Day +1. This elevated implied volatility suggests that options traders are anticipating a much larger reaction than typical earnings-driven moves, likely reflecting the proximity of the Q4 2026 Phase 3 ARCHER II data readout and the potential U.S. BLA filing for ANX005. The options market appears to be pricing in the possibility of a major catalyst beyond the quarterly results themselves.

Part 3: What Analysts Are Saying

Annexon holds a bullish consensus among analysts, with an average recommendation of 4.42 out of 5.0, reflecting strong conviction in the company's late-stage pipeline. The breakdown shows 8 Strong Buys, 1 Moderate Buy, and 3 Holds, with no Sell or Strong Sell ratings. This distribution has remained unchanged over the past month, indicating stable sentiment as the company approaches key regulatory and clinical milestones.

The mean price target of $17.00 implies 305% upside from the current price of $4.20, with a wide range of estimates spanning from a low of $7.00 to a high of $27.00. The high-end target reflects optimism about the commercial potential of tanruprubart and vonaprument if both programs achieve regulatory approval and demonstrate differentiated clinical profiles. The low-end estimate of $7.00 still implies 67% upside, suggesting that even the most conservative analysts see meaningful value in the current risk-reward setup.

The sentiment trend is classified as "unchanged," with the average recommendation and rating counts holding steady over the past month. This stability suggests that analysts are in a wait-and-see mode ahead of the Q4 2026 catalysts, with limited new information prompting revisions to ratings or targets. However, the concentration of Strong Buy ratings underscores that the analyst community remains constructive on Annexon's ability to execute on its regulatory and commercialization strategy, particularly for ANX005 in Guillain-Barré syndrome, where the company could capture a first-mover advantage in an underserved market.

Part 4: Technical Picture

Annexon's technical setup heading into earnings shows improving short-term momentum but remains under pressure on longer-term timeframes. The Barchart Technical Opinion currently registers a 56% Sell signal, a notable improvement from 88% Sell one week ago and 100% Sell one month ago. This weakening of the sell signal suggests that near-term buying interest has emerged, though the stock has not yet broken into bullish territory.

The stock is trading at $4.20, positioned above its 5-day ($4.13), 10-day ($4.02), 20-day ($3.90), and 50-day ($4.11) moving averages, indicating short-term strength. However, it remains below the 100-day ($4.75) and 200-day ($5.16) moving averages, reflecting longer-term downtrend pressure. The recent bounce off the 20-day moving average suggests that buyers have stepped in at lower levels, but the stock has yet to reclaim the key 100-day moving average, which would signal a more durable reversal.

Timeframe Analysis:

• Short-term (50% Sell): The short-term signal is neutral-to-bearish, reflecting mixed momentum as the stock consolidates near recent highs but lacks a decisive breakout.
• Medium-term (50% Sell): The medium-term outlook mirrors the short-term, suggesting that the stock is in a transitional phase with no clear directional bias.
• Long-term (100% Sell): The long-term signal remains firmly bearish, indicating that the broader trend is still down despite recent stabilization.

Trend Characteristics: The trend is characterized by Average strength and a Weakening direction, suggesting that while the stock has stabilized and shown signs of short-term improvement, the underlying momentum is not yet strong enough to confirm a sustained reversal.

The technical picture presents a cautiously constructive setup for earnings, with the stock showing signs of stabilization after a prolonged decline. The fact that the Barchart Technical Opinion has improved from 100% Sell to 56% Sell over the past month indicates that selling pressure has eased, and the stock is trading above all short-term moving averages. However, the failure to reclaim the 100-day moving average at $4.75 and the persistent long-term sell signal suggest that the stock remains vulnerable to downside if earnings or upcoming clinical catalysts disappoint.

Key resistance lies at the 100-day moving average ($4.75), which would need to be reclaimed to signal a more meaningful technical breakout. Support is likely at the 20-day moving average ($3.90), which has acted as a floor in recent weeks. The 18.62% expected move priced into options suggests that the market is anticipating a significant reaction, and the technical setup indicates that the stock could break out above resistance or retest support depending on the tone of the earnings report and any updates on the Q4 2026 clinical and regulatory catalysts.